Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by gebremeskelon Nov 15, 2024 10:37am
105 Views
Post# 36314823

Carlyle: EU approves acquisition of Vantive

Carlyle: EU approves acquisition of Vantivehttps://www.marketscreener.com/quote/stock/THE-CARLYLE-GROUP-INC-10531255/news/Carlyle-EU-approves-acquisition-of-Vantive-48379358/

November 15, 2024 at 08:55 am EST
 
The European Commission has approved, under the EU Merger Regulation, the acquisition of sole control of Vantive, the renal care division of Baxter International by the Carlyle Group in the USA.
 
The transaction mainly concerns the supply of renal replacement therapy products.
 
The Commission concluded that the notified transaction would not raise competition concerns, given the limited market positions of the companies resulting from the proposed transaction.
 
The notified transaction was examined under the simplified merger review procedure.
<< Previous
Bullboard Posts
Next >>